Skip to Content

Roche Holding AG

View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
CHF 155.00JymDzbdjmxzcv

Roche's Pharma Pipeline and Diagnostics Innovation Support a Wide Moat

Business Strategy and Outlook

We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare giant is in a unique position to guide global health care into a safer, more personalized, and more cost-effective endeavor. Strong information sharing continues between Genentech and Roche researchers, boosting research and development productivity and personalized medicine offerings that take advantage of Roche's diagnostic expertise.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of ROG so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center